Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ studyFlorence Joly, Michel Fabbro, Dominique Berton, et al.
JNCI Cancer Spectrum|December 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)Florence Joly, Fernando Bazan, Delphine Garbay, et al.
The British Journal of Dermatology|October 11, 2024
Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcomaLouise van der Weyden, Martin Del Castillo Velasco-Herrera, Saamin Cheema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trialFélix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trialGuillaume Beinse, Valerie Taly, Alexandra Leary, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Nature Communications|August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trialFlorence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
BMJ Open|September 4, 2025
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE studyJerome Alexandre, Philippe Boudier, Elise Lavit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Pageof 11